Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection

Zheng, Shuqin; Liu, Longgen; Lu, Jicun; Zhang, Xiujun; Shen, Huan; Zhang, Hongyu; Xue, Yuan; Lin, Lin

doi:10.1097/md.0000000000017590

Cited by 10 publications

(7 citation statements)

References 23 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the estimated glomerular filtration rate (eGFR) remained stable in patients with impaired kidney function during 3-year real-world studies conducted in Europe[ 4 ]. Our previous study also showed that eGFR remained stable irrespective of prior LC or age > 65 years old in a two-year real-world study[ 5 ]. However, potential nephrotoxicity during long-term treatment of TDF remains a concern in clinical practice.…”

Section: Introductionmentioning

confidence: 78%

Dynamic changes of estimated glomerular filtration rate are conversely related to triglyceride in non-overweight patients

Liu¹,

Zhang²,

Xue³

et al. 2022

World J Clin Cases

Self Cite

View full text Add to dashboard Cite

BACKGROUND Correlation between Triglyceride (TG) and estimated glomerular filtration rate (eGFR) remains largely unknown in overweight and non-overweight patients. AIM To investigated the dynamic changes of eGFR and lipid profiles during 3-year tenofovir disoproxil fumarate (TDF) treatment in patients with chronic hepatitis B (CHB) and overweight. METHODS A total of 202 CHB patients who received TDF treatment at the Third People's Hospital of Changzhou (Changzhou, China) and Nanjing Drum Tower Hospital (Nanjing, China) between January 2016 and May 2018 were retrospectively enrolled. According to the body mass index (BMI) at the initiation of TDF treatment, CHB patients were divided into overweight (BMI ≥ 25 kg/m 2 ) and non-overweight (BMI < 25 kg/m 2 ) groups. Logistic regression was applied for the analysis of risk factors for eGFR < 90 mL/(min·1.73 m 2 ). RESULTS There is no significant difference in hepatitis B virus DNA (HBV DNA) negativity and hepatitis Be antigen (HBeAg) loss between patients with overweight and non-overweight (both P > 0.05). More patients in non-overweight group achieved alanine aminotransferase normalization compared with those in overweight group ( χ 2 = 11.036, P < 0.01). In non-overweight patients, the eGFR significantly declined in the 1 st year ( P < 0.01), then remained at a relatively lower level. TG significantly declined in the 2 nd year ( P = 0.02) and increased in the 3 rd year. Moreover, TG was negatively correlated with GFR at the four-time points ( P = 0.002, 0.030, 0.007, 0.008, respectively). In overweight patients, eGFR and TG remained relatively stable during the 3-year treatment, and eGFR showed no significant relationship with TG. Moreover, multivariate analysis showed that age [ P < 0.01, 95%CI (0.97-1.005)] and baseline eGFR [ P < 0.01, 95%CI (5.056-33.668)] were independent risk factors for eGFR < 90 mL/(min·1.73 m 2 ) at the 3 rd year. CONCLUSION Dynamic changes in renal function were conversely related to TG during TDF treatment in patients with CHB and normal BMI, but not with overweight.

show abstract

Section: Introductionmentioning

confidence: 78%

Dynamic changes of estimated glomerular filtration rate are conversely related to triglyceride in non-overweight patients

Liu¹,

Zhang²,

Xue³

et al. 2022

World J Clin Cases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Secondly, concerns about renal toxicity should not limit access to treatment; we found that untreated CHB patients also had a risk of CKD progression (consistent with a previous cohort study [ 28 ]), which was not significantly different from the risk in treated patients. Previous studies found that risk factors associated with renal function decline in CHB patients include old age, hypertension, diabetes, baseline impairment in eGFR, and use of diuretics [ 48 – 51 ]. Therefore, concerns about nephrotoxicity may be more pertinent in these subgroups, and risks should be assessed on a case-by-case basis.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

et al. 2021

View full text Add to dashboard Cite

Background Current clinical guidelines recommend treating chronic hepatitis B virus (HBV) infection in a minority of cases, but there are relatively scarce data on evolution or progression of liver inflammation and fibrosis in cases of chronic HBV (CHB) that do not meet treatment criteria. We aimed to assess the impact of TDF on liver disease, and the risk of renal impairment in treated CHB patients in comparison to untreated patients. Methods We studied a longitudinal ethnically diverse CHB cohort in the UK attending out-patient clinics between 2005 and 2018. We examined TDF treatment (vs. untreated) as the main exposure, with HBV DNA viral load (VL), ALT, elastography scores and eGFR as the main outcomes, using paired tests and mixed effects model for longitudinal measurements. Additionally, decline of eGFR during follow-up was quantified within individuals by thresholds based on clinical guidelines. Baseline was defined as treatment initiation for TDF group and the beginning of clinical follow-up for untreated group respectively. Results We included 206 adults (60 on TDF, 146 untreated), with a median ± IQR follow-up duration of 3.3 ± 2.8 years. The TDF group was significantly older (median age 39 vs. 35 years, p = 0.004) and more likely to be male (63% vs. 47%, p = 0.04) compared to the untreated group. Baseline difference between TDF and untreated groups reflected treatment eligibility criteria. As expected, VL and ALT declined significantly over time in TDF-treated patients. Elastography scores normalised during treatment in the TDF group reflecting regression of inflammation and/or fibrosis. However, 6/81 (7.4%) of untreated patients had a progression of fibrosis stage from F0-F1 to F2 or F3. There was no evidence of difference in rates or incidence of renal impairment during follow-up in the TDF vs. untreated group. Conclusions Risk of liver inflammation and fibrosis may be raised in untreated patients compared to those receiving TDF, and TDF may benefit a larger percentage of the CHB population.

show abstract

“…There are 240-400 million cases of CHB all over the world which is endemic in sub-Saharan Africa and Asia-Pacific region due to the high rate of perinatally and early childhood infection [2], [19], [20], [21]. In the western world, CHB is mainly caused by unhealthy lifestyle such as high-risk sexual behavior and injection drug use [1], [2], [18], [19]. We found that both groups had a male population is more affected than women.…”

Section: Discussionmentioning

confidence: 99%

“…Other disadvantages of nucleotide analogs in treating CHB are indefinite duration of treatment, risk of developing resistance, and less HBeAg and HBsAg conversions [9], [15]. Only one single-centered study was found that has discussed the efficacy and side effects of tenofovir in Indonesia [16,17,18]. Moreover, Indonesia is a country with a diversity of cultures, religions, and races so that the research on the efficacy of TDF against CHB infection regarding that heterogeneity is in need.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of 24-week Administration of Tenofovir Disoproxil Fumarate in the Management of Naïve Chronic Hepatitis B

Darmadi¹,

Siregar²

2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Chronic hepatitis B (CHB) is becoming a common liver abnormality worldwide. Thus, a series of good management is needed to prevent the progression and complications of hepatitis B infection. Tenofovir disoproxil fumarate (TDF) is one of the drugs of choice that’s used for CHB management. AIM: Limited studies were found regarding the efficacy of tenofovir in dealing with CHB. Hence, the aim of this study is to determine the efficacy of TDF administration for 24 weeks in subjects with naïve CHB in Medan, Indonesia. METHODS: Retrospective study was conducted in Haji Adam Malik Hospital Medan, Indonesia, between January and December 2019. Subjects were CHB patients aged 18 years or older and were treated TDF for 24 weeks. Demographic, clinical, and CHB disease progression parameters (serum alanine aminotransferase [ALT], hepatitis B envelope antigen [HBeAg], and hepatitis B virus deoxyribonucleic acid [HBV DNA]) data were obtained. RESULTS: One hundred and twenty subjects were obtained and divided into 2 groups: HBeAg positive and HBeAg negative. Mean age of subjects was 46.5 ± 10.36 years in HBeAg positive group and 48.6 ± 10.67 years HBeAg negative group, with predominant males’ subjects in both groups (58.3% vs. 61.7%, respectively). Serum ALT normalization and undetectable serum HBV DNA were observed in more than 70% and 65% of subjects in both groups, respectively (both p < 0.001). Serum HBeAg loss was achieved in 10.8% subjects (p < 0.001). No subject showed serum HbsAg loss. CONCLUSION: Our results are consonant with current clinical guidelines and other evidence literature. For both HBeAg-positive and HBeAg-negative populations, TDF administration for 24 weeks has good efficacy in naïve CHB patients.

show abstract

Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection

Abstract: Supplemental Digital Content is available in the text

Cited by 10 publications

References 23 publications

Dynamic changes of estimated glomerular filtration rate are conversely related to triglyceride in non-overweight patients

Dynamic changes of estimated glomerular filtration rate are conversely related to triglyceride in non-overweight patients

Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

Efficacy of 24-week Administration of Tenofovir Disoproxil Fumarate in the Management of Naïve Chronic Hepatitis B

Contact Info

Product

Resources

About